CD8A and neoplasm: These dendritic cell vaccines, when used in conjunction with an anti-fibrotic agent, have effectively activated both innate and adaptive immune responses, leading to enhanced NK cell function, boosted anti-tumor humoral responses, and potentiated cytotoxic CD8+ T cell activity across diverse tumor models (218).